Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990 Jan;7(1):21-7.
doi: 10.1023/a:1015823206607.

Irreversible binding of tolmetin glucuronic acid esters to albumin in vitro

Affiliations

Irreversible binding of tolmetin glucuronic acid esters to albumin in vitro

A Munafo et al. Pharm Res. 1990 Jan.

Abstract

Tolmetin glucuronide (TG), extracted and purified from human urine, was incubated with albumin in vitro. The degradation profile and irreversible binding to protein were investigated and kinetic parameters calculated. Standard conditions were as follows: TG, 30 micrograms/ml; human serum albumin (HSA), 3%; pH 7.45; 37 degrees C. Lower pH enhanced TG stability and reduced both the extent and the rate of irreversible binding. HSA also increased TG stability, compared to protein-free buffer, but the opposite was observed with bovine serum albumin (BSA). With BSA, irreversible binding was much less, but the rate of adduct formation was the same as with HSA. Essentially fatty acid free HSA behaved similarly to HSA. Preincubation of HSA with warfarin, or diazepam, or an excess of tolmetin, did not influence irreversible binding significantly. In buffer, acyl migration led predominantly to one isomer. This isomer bound irreversibly to HSA, although more slowly and to a lesser extent than the beta 1-isomer. Incubation of TG with poly-L-lysine also resulted in irreversible binding but to a lesser extent than with HSA. Our results suggest that there is more than one binding mechanism, with the preferential pathway a function of the isomers present and the experimental conditions.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Clin Pharmacol Ther. 1988 Jul;44(1):107-14 - PubMed
    1. Adv Exp Med Biol. 1986;197:431-41 - PubMed
    1. Drug Metab Dispos. 1985 May-Jun;13(3):318-20 - PubMed
    1. Biochem Pharmacol. 1974 Oct 15;23 (20):2785-94 - PubMed
    1. Adv Exp Med Biol. 1986;197:423-9 - PubMed

Publication types

LinkOut - more resources